214390 — Kyongbo Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual income statement for Kyongbo Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	170,660	196,265	216,357	238,556	264,104
Cost of Revenue
Gross Profit	35,360	44,418	63,075	82,420	102,304
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	177,158	194,872	210,856	228,102	260,585
Operating Profit	-6,498	1,393	5,502	10,454	3,519
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-9,933	-615	2,172	4,903	449
Provision for Income Taxes
Net Income After Taxes	-7,495	611	2,974	4,639	182
Net Income Before Extraordinary Items
Net Income	-7,495	611	2,974	4,639	182
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-7,495	611	2,974	4,639	182
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-319	22.2	126	194	10.2
Dividends per Share